Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

A Prospective Evaluation of Bleeding Risk of Anticoagulant and Antiplatelet Therapy for Interventional Techniques

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00625248

Enrollment

12000

Registered

2008-02-28

Start date

2008-02-29

Completion date

2010-01-31

Last updated

2013-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding

Brief summary

This study will evaluate bleeding risk and differences in outcomes in patients receiving and not receiving anticoagulant or antiplatelet therapy

Detailed description

1. To evaluate bleeding risk in interventional procedures in patients with or without antiplatelet and/or anticoagulant therapy. 2. To evaluate differences in outcomes in patients not receiving any anticoagulant or antiplatelet therapy compared to patients receiving various types of drugs with anticoagulant or antiplatelet therapeutic effects. 3. To evaluate and compare the adverse event profiling all patients.

Interventions

DRUGAntithrombotics

With or without or discontinuted use of Antithrombotics

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects undergoing interventional techniques. Subjects who were able to give voluntary, written informed consent.

Exclusion criteria

* All those things, patients on heparin, dextran, and low molecular heparin

Design outcomes

Primary

Measure	Time frame
To evaluate for differences between the patients undergoing interventional techniques with or without anticoagulant or antiplatelet therapy.	24 months

Secondary

Measure	Time frame
To assess adverse events in all patients.	24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026